1. Kolh P., Wijns W., Danchin N. et al. Guidlines on myocardial revascularization. Task Force on myocardial revascularization of the European Society Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Intervention (EAPCI). Eur. J. Cardiothorac. Surg. 2010; 38: 1–52.
2. Nicholls S. J., Tuzcu E. M., Kalidindi S. et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J. Аm. Coll. Cardiol. 2008; 52 (4): 25–262.
3. Лупанов В. П. Безболевая ишемия миокарда: диагностика, медикаментозное и хирургическое лечение, прогноз (обзор литературы). Consilium. Medicum. 2012; 14 (10): 36–44. Lupanov V. P. Bezbolevaya ischemiya miokarda: diagnostika, medikamentoznoe I hirurgicheskoe lechenie, prognoz (obzor literaturi). Consilium. Medicum. 2012; 14 (10): 36–44..
4. Терещенко С. Н., Джаиани Н. А., Голубев А. В. Ишемическая болезнь сердца и сахарный диабет. Consilium. Medicum. 2005; 5: 364–368. Tereschenko S. N., Djaiani N. A., Golubev A. V. Ischemicheskaya bolezn’ serdtsa i saharniy diabet. Consilium. Medicum. 2005; 5: 364–368..
5. Berry C., Tardif J.-C., Bourassa M. G. Coronary heart disease in patient with diabetes. Pt I: Recent advances in prevention and noninvasive management. J. Am. Coll. Cardiol. 2007; 49: 631–642.
6. Грачева С. А., Клефортова И. И., Шамхалова М. Ш. Распространенность сочетанного атеросклеротического поражения сосудов у больных сахарным диабетом. Сахарный диабет. 2012; 1: 49–55. Gracheva S. A., Klefortova I. I., Shamkhalova M. Sh. Rasprostranennost’ sochetannogo ateroskleroticheskogo porazheniya sosudov u bol’nih s saharnim diabetom. Saharniy diabet. 2012; 1: 49–55..
7. Scirica B., Morrow D., Cannon C. et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin. Chem. 2007; 53: 18001–18007.
8. Mc. Cullough P. A., Peacock F. W., O’Neil B. et al. Capturing the pathophysiology of acute coronary syndromes with circulating biomarkers. Rev. Cardiovasc. Med. 2010; 11: 31–32.
9. Дедов И. И., Шестакова М. В. Алгоритмы специализированной медицинской помощи больным с сахарным диабетом. М.: Информполиграф. 2013; 26. Dedov I. I., Shestakova M. V. Algoritmi spetsializirovannoi meditsinskoi pomoschi bol’nim s saharnim diabetom. Moscow: Informpoligraf. 2013; 26..
10. Serruys P. W., Onuma Y., Garg S. et al. Assessment of the SYNTAX score in the Syntax study. EuroInterv. 2009; 5(1): 50–56.
11. Дедов И. И., Шестакова М. В. Сахарный диабет и артериальная гипертензия. М.: МИА. 2006; 343. Dedov I. I., Shestakova M. V. Saharniy diabet I arterial’naya gipertensiya. Moscow: MIA. 2006; 343..
12. Clark R., Kupper T. Old meets new: the interaction between innate and adaptive immunity. J. Invest Dermatol. 2005; 125 (4): 629–637.
13. Хаитов Р. М., Игнатьева Г. А., Сидорович И. Г. Иммунология. Норма и патология: учебник. 3-е изд., перераб. и доп. М.: Медицина; 2010; 10–15. Khaitov R. M., Ignat’eva G. A., Sidorovich I. G. Immunologia. Norma I patologiya: Uchebnik. 3-е izd., pererab. i dop. Moscow: Meditsina; 2010; 10–15..
14. Gibson J., Gow N., Wong S. Y. Expression and Funktion of innate Pattent Recognition Receptors in T and B cells. Immun., Endoc &Metab. Agents in Med. Chem. 2010; 10: 11–20.
15. Virtue A., Wang H., Yang X. F. MicroRNAs and toll-like receptor/interleukin-1 receptor signalling. J. Hematol. Oncol. 2012; 5: 66.
16. Harskamp R. E. and van Ginkel M. W. Acute respiratory tract infections: a potential trigger for the acute coronary syndrome. Ann. Med. 2008; 40: 121–126.
17. Gill R., Tsung A., Billiar T. R. Linking oxidative stress to inflammation: toll-like receptors. Free Radic. Biol Med. 2010; 48: 1121–1132.
18. Cario E. Toll-like Receptors in Inflammatory Bowel Diseases: A Decade Later. Inflamm. Bowel. Dis. 2010; 16: 1583–1597.
19. Brown J., Wang H., Hajishengallis G. N. et al. TLRsignaling networks: an integration of adaptor molecules, kinases, and cross – talk. J. Dent. Res. 2011; 90: 4174–4227.
20. Suzuki T., Kobayashi M., Isatsu K. et al. Mechanisms involved in apoptosis of human macrophages induced by lipopolysaccharide from Actinobacillus actinomycetemcomitans in the presence of cycloheximide. Infec.t Immun. 2007; 72: 18561–18565.
21. Wong F. S., Wen L. Toll-like receptors and diabetes. Ann NY Acad Sci. 2008; 1150: 123–132.
22. Tieri P., Termanini A., Bellavista E. et al. Charting the NF-κB pathway interactome map. PLoS One. 2012; 7: 32678.
23. Ruiz-Ortega M., Esteban V., Egido J. The regulation of the inflammatory response through NF-kB pathway in cardiovascular disease. Trends Cardiovasc. Med. 2007; 17 (1): 19–25.
24. Manolakis A. C., Kapsoritakis A. N., Tiaka E. K. et al. TLR4 gene polymorphisms: evidence for protection against type 2 diabetes but not for diabetes-associated ischaemic heart disease. Eur. J. Endocrinol. 2011; 165 (2): 261–267.
25. Yang I. A., Holloway J. W., Ye S. TLR4 Asp 299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis. 2003; 170: 187–190.
26. Ameziane N., Beillat T., Verpillat P. et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 61–64.
27. Kiechl S., Lorenz E., Reindel M. et al. Toll-like receptors 4 polymorphisms and atherogenesis. N. Engl. J. Med. 2002; 347 (3): 85–92.
28. Lee J. Y., Zhao L., Youn H. S. et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J. Biol. Chem. 2004; 279: 16971–16979.
29. Wolowczuk I., Verwaerde C., Viltart O. et al. Feeding Our Immune System: Impact on Metabolism. Clin. Dev. Immunol. 2008: 639803. Published online 2008 Feb 25. doi: 10.1155/2008/639803.
30. Груздева О. В., Барбараш О. Л., Акбашева О. Е. Взаимосвязь ингибитора активатора плазминогена и свободных жирных кислот с инсулинорезистентностью у больных инфарктом миокарда. Сахарный диабет. 2011; 4: 18–23.
31. Gruzdeva O. V., Barbarash O. L., Akbasheva O. E. Vzaimosvyaz’ ingibitora aktivatora plasminogena i svobodnih zhirnih kislot s insulinoresistentnost’yu u bolnih infarktom miokarda. Saharnii diabet. 2011; 4: 18–23..
32. Schaeffler A., Gross P., Buettner R. et al. Fatty acidinduced induction of Toll-like receptor-4/nuclear factorkappaB pathway in adipocytes links nutritional signalling with innate immunity. Immunology. 2009; 126: 233–245.
33. Kim S. J., Choi Y., Choi Y. H. et al. Obesity activates toll-like receptor-mediated proinflammatory signaling cascades in the adipose tissue of mice. J. Nutr. Biochem. 2012; 23: 113–122.
34. Fresno M., Alvarez R., Cuesta N. Toll-like receptors, inflammation, metabolism and obesity. Arch Physiol. Biochem. 2011; 117: 151–164.
35. Shi H., Kokoeva M. V., Inouye K. et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. Journal of Clinical Investigation. 2006; 116 (11): 3015–3025.
36. Radin M. S., Sinha S., Bhatt B. A. et al. Inhibition or deletion of the lipopolysaccharide receptor Toll-like receptor-4 confers partial protection against lipid-induced insulin resistance in rodent skeletal muscle. Diabetologia. 2008; 51: 336–346.
37. Dasu M. R., Jialal I. Amelioration of wound healing in diabetic toll-like receptor-4 knockout mice. J. Diabetes Complications. 2013; 27 (5): 417–421.
38. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375 (9733): 2215–2222.